ReviewCurrent hematologic malignancy reports2012
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Review in Current hematologic malignancy reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.Blood cancer journal · 2015Trial
- Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023Review
- Cancer-associated fibroblasts in acute leukemia.Frontiers in oncology · 2022Review
- Article
- Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.Leukemia · 2019Article
- Article
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.Leukemia · 2017Article
- New Therapeutic Approaches in Polycythemia Vera.Clinical lymphoma, myeloma & leukemia · 2015Review
- Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Bone marrow transplantation · 2015Review
- The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.Mediators of inflammation · 2015Review
- Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).Bone marrow transplantation · 2014Article
- Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.Molecular oncology · 2014Article
- Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.International journal of general medicine · 2014Article
- Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Molecular diagnosis & therapy · 2012Review
- Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it is associated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylating agents, and JAK2 inhibition, to try to alter the course of the disease and improve outcomes. This review focuses on the latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population.
Indexed as
Identifiers
22170483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.